MedTrace Logo

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

NCT07152756 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 418

Last updated 2025-09-03

No results posted yet for this study

Summary

A prospective, single-center, observational study to compare the risk of gastric retention and endoscopic mucosal visibility between the exposure group (one-week discontinuation of semaglutide before EGD) and non-exposure group (no semaglutide use before EGD)

Conditions

  • Gastric Retention

Interventions

PROCEDURE

Esophagogastroduodenoscopy

Assess the gastric retention and the endoscopic mucosal visibility score during esophagogastroduodenoscopy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Danian Ji, M.D. · Huadong Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2028-09-15
Completion
2028-09-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07152756 on ClinicalTrials.gov